| Iredell Memorial Hospital Inc | |
| 557 Brookdale Drive, Statesville, North Carolina 28677 | |
| (704) 878-4541 | |
| Name | Iredell Memorial Hospital Inc |
|---|---|
| Location | 557 Brookdale Drive, Statesville, North Carolina |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 48 |
| Occupancy Rate | 72.71% |
| Medicare ID (CCN) | 345306 |
| Legal Business Name | Iredell Memorial Hospital Incorporated |
| Ownership Type | Non Profit - Other |
| NPI Number | 1760462196 |
| Organization Name | IREDELL MEMORIAL HOSPITAL, INC |
| Doing Business As | IREDELL MEMORIAL HOSPITAL SKILLED NURSING FACILITY |
| Address | 557 Brookdale Dr, Statesville, NC 28677 |
| Phone Number | 704-873-5661 |
News Archive
Merrimack Pharmaceuticals, Inc. announced today that the first patient has been dosed in a randomized Phase 2 clinical trial of MM-121, a fully human monoclonal antibody that targets ErbB3, combined with paclitaxel in the neoadjuvant setting of HER2-negative breast cancer patients.
The controversial practice has been standard in many teaching hospitals for decades, its safety and ethics largely unquestioned and its existence unknown to those most affected: people undergoing surgery.
By engineering antibacterial enzymes, Dartmouth investigators led by Karl Griswold, PhD are using novel strategies to target the prevalent drug-resistant bacterium Staphylococcus aureus.
NicOx S.A. today announced that the European Medicines Agency (EMEA) has validated the Marketing Authorization Application (MAA) for naproxcinod, which was submitted through the centralized procedure in December 2009. NicOx is seeking approval for an indication for the relief of the signs and symptoms of primary osteoarthritis. This follows the acceptance for filing of a New Drug Application (NDA) by the US Food and Drug Administration (FDA) in November 2009.
Oncolytics Biotech Inc. announced today that a U.S. Phase I study of REOLYSIN® in combination with FOLFIRI (Folinic Acid (leucovorin) + Fluorouracil (5-FU) + Irinotecan) in patients with oxaliplatin refractory/intolerant Kras mutant colorectal cancer (REO 022) is now open to enrollment. The principal investigator is Dr. Sanjay Goel of the Montefiore Medical Center at The Albert Einstein College of Medicine in New York.
› Verified 4 days ago
| NPI Number | 1821284761 |
| Organization Name | IREDELL MEMORIAL HOSP SNF ICF |
| Address | 557 Brookdale Drive, Statesville, NC 28677 |
| Phone Number | 704-873-5661 |
News Archive
Merrimack Pharmaceuticals, Inc. announced today that the first patient has been dosed in a randomized Phase 2 clinical trial of MM-121, a fully human monoclonal antibody that targets ErbB3, combined with paclitaxel in the neoadjuvant setting of HER2-negative breast cancer patients.
The controversial practice has been standard in many teaching hospitals for decades, its safety and ethics largely unquestioned and its existence unknown to those most affected: people undergoing surgery.
By engineering antibacterial enzymes, Dartmouth investigators led by Karl Griswold, PhD are using novel strategies to target the prevalent drug-resistant bacterium Staphylococcus aureus.
NicOx S.A. today announced that the European Medicines Agency (EMEA) has validated the Marketing Authorization Application (MAA) for naproxcinod, which was submitted through the centralized procedure in December 2009. NicOx is seeking approval for an indication for the relief of the signs and symptoms of primary osteoarthritis. This follows the acceptance for filing of a New Drug Application (NDA) by the US Food and Drug Administration (FDA) in November 2009.
Oncolytics Biotech Inc. announced today that a U.S. Phase I study of REOLYSIN® in combination with FOLFIRI (Folinic Acid (leucovorin) + Fluorouracil (5-FU) + Irinotecan) in patients with oxaliplatin refractory/intolerant Kras mutant colorectal cancer (REO 022) is now open to enrollment. The principal investigator is Dr. Sanjay Goel of the Montefiore Medical Center at The Albert Einstein College of Medicine in New York.
› Verified 4 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
Merrimack Pharmaceuticals, Inc. announced today that the first patient has been dosed in a randomized Phase 2 clinical trial of MM-121, a fully human monoclonal antibody that targets ErbB3, combined with paclitaxel in the neoadjuvant setting of HER2-negative breast cancer patients.
The controversial practice has been standard in many teaching hospitals for decades, its safety and ethics largely unquestioned and its existence unknown to those most affected: people undergoing surgery.
By engineering antibacterial enzymes, Dartmouth investigators led by Karl Griswold, PhD are using novel strategies to target the prevalent drug-resistant bacterium Staphylococcus aureus.
NicOx S.A. today announced that the European Medicines Agency (EMEA) has validated the Marketing Authorization Application (MAA) for naproxcinod, which was submitted through the centralized procedure in December 2009. NicOx is seeking approval for an indication for the relief of the signs and symptoms of primary osteoarthritis. This follows the acceptance for filing of a New Drug Application (NDA) by the US Food and Drug Administration (FDA) in November 2009.
Oncolytics Biotech Inc. announced today that a U.S. Phase I study of REOLYSIN® in combination with FOLFIRI (Folinic Acid (leucovorin) + Fluorouracil (5-FU) + Irinotecan) in patients with oxaliplatin refractory/intolerant Kras mutant colorectal cancer (REO 022) is now open to enrollment. The principal investigator is Dr. Sanjay Goel of the Montefiore Medical Center at The Albert Einstein College of Medicine in New York.
› Verified 4 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 0 |
| Total Amount of Fines in Dollars | $0 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 0 |
| Experience Measure | Provider | National Avg. |
|---|